Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | 10% owner | October 01, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date October 01, 2026 · Filed October 09, 2026 · Amendment
Jointly reported with GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.50 | IndirectSee footnote | 7,172,000 |
Reported balance
After 2026-10-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-10-01 · Purchase · Acquired 7,172,000 · Balance 7,172,000 F3: Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant. F2: The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90. F4: The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date"). F5: The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma. F1: The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
F2: The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90.
F3: Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant.
F4: The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date").
F5: The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 9, 2026 18:39 UTC Amendment | Pyxis Oncology, Inc. PYXS · Entity 5986 | PurchaseCommon Stock Purchase Warrant · Derivative | 7,172,000 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0000919574-26-006815 · ownership.xml · derivative · entry 1 GordonMD Global Investments LP · CIK 0002039349 · 10% owner GordonMD Long Biased Master Fund LP · CIK 0002103789 · 10% owner GordonMD Long Biased GP LLC · CIK 0002103778 · 10% owner Gordon Craig D · CIK 0002103811 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,172,000 Underlying: Common Stock · 7,172,000 shares Expires not disclosed F3 · derivative.exercise_price: Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant. F2 · price: The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90. F4 · derivative.exercise_date: The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date"). F5 · derivative.expiration_date: The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma. F1 · ownership.nature: The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 16:35 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | PurchaseCommon Stock Purchase Warrant · Derivative | 7,546,766 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0000919574-26-006609 · ownership.xml · derivative · entry 2 GordonMD Global Investments LP · CIK 0002039349 · 10% owner GordonMD Long Biased Master Fund LP · CIK 0002103789 · 10% owner GordonMD Long Biased GP LLC · CIK 0002103778 · 10% owner Gordon Craig D · CIK 0002103811 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,546,766 Underlying: Common Stock · 7,546,766 shares Expires not disclosed F3 · derivative.exercise_price: Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant. F2 · price: The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90. F4 · derivative.exercise_date: The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date"). F5 · derivative.expiration_date: The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma. F1 · ownership.nature: The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 16:35 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | PurchaseCommon Stock, par value $0.001 per share ("Common Stock") | 5,517,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-26-006609 · ownership.xml · nonDerivative · entry 1 GordonMD Global Investments LP · CIK 0002039349 · 10% owner GordonMD Long Biased Master Fund LP · CIK 0002103789 · 10% owner GordonMD Long Biased GP LLC · CIK 0002103778 · 10% owner Gordon Craig D · CIK 0002103811 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 15,541,909 F2 · price: The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90. F1 · ownership.nature: The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.